
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based ...
Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targets OBT to receive up to US$36 million upfront payments and may be eligible to receive …